We investigate the potential association between leucine-rich repeat kinase 2 (LRRK2) mutations and voice. Sustained phonations ('aaah' sounds) were recorded from 7 individuals with LRRK2-associated Parkinson's disease (PD), 17 participants with idiopathic PD (iPD), 20 non-manifesting LRRK2-mutation carriers, 25 related non-carriers, and 26 controls. In distinguishing LRRK2-associated PD and iPD, the mean sensitivity was 95.4% (SD 17.8%) and mean specificity was 89.6% (SD 26.5%). Voice features for non-manifesting carriers, related non-carriers, and controls were much less discriminatory. Vocal deficits in LRRK2-associated PD may be different than those in iPD. These preliminary results warrant longitudinal analyses and replication in larger cohorts.
Introduction
Voice impairment may be one of the earliest motor indicators of idiopathic Parkinson's disease (iPD) [1] , and is typically characterized by breathiness, roughness, reduced loudness, and vocal tremor [1] [2] [3] [4] . It is estimated that between 70 and 90% of people with PD (PWP) experience vocal impairment [2, 5, 6] , and nearly one-third of PWP report voice-related problems as one of their main disease-related limitations [6] .
Past work has demonstrated that objective measures of vocal impairment can be used to distinguish participants with iPD from controls with a high accuracy (mean sensitivity and mean specificity > 90%) [7] [8] [9] [10] [11] [12] [13] [14] [15] . The extent of vocal dysfunction has also been shown to be associated with disease severity [3, 16, 17] . Moreover, for symptom monitoring, voicebased measures have been used to accurately replicate both the motor and total Unified Parkinson's Disease Rating Scale (UPDRS) assessment (within 2 points from the clinicians' estimate) [18] . Recently, abnormalities in speech production have also been reported in participants with idiopathic rapid eye movement (REM) sleep behaviour disorder [19, 20] .
These findings encourage further investigation of voice analysis as a reliable, non-invasive, and scalable tool that may also identify prodromal PD.
Leucine-rich repeat kinase 2 (LRRK2) mutations are the most common cause of genetically-determined PD [21] . The opportunity to intervene with disease-modifying therapy early in the neurodegenerative process makes identifying the prodromal state important. To investigate the presence of voice abnormalities in populations at increased risk to develop PD, in this study we analyse voice-based measures in multiplex families carrying a mutation in the gene for LRRK2. The goals of this pilot study were thus twofold.
First, we aimed to determine if voice can be used to discriminate participants with LRRK2-associated PD from idiopathic PD. Second, we examined if there are any differences in voice between non-manifesting carriers of a LRRK2 mutation when compared to related nonmanifesting non-mutation carriers and unrelated healthy controls.
Methods

Study participants
Probands with LRRK2 mutations were identified at Toronto Western Hospital and all available blood relatives were invited to participate. iPD patients and healthy individuals (devoid of any neurologic disease or family history of PD) were recruited at Toronto Western Hospital. iPD was defined as individuals with PD, according to clinical diagnosis by a movement disorder specialist, in the absence of a family history of the disease in a first or second-degree relative. Seven participants with LRRK2-PD (p.P.G2019S (5) or L1795F (2)), 17 participants with iPD, 20 non-manifesting carriers of LRRK2 mutations (p.G2019S (18) , L1795F (2)), 25 related non-manifesting non-carriers, and 26 healthy controls were recruited. The presence or absence of a LRRK2 mutation was evaluated in all participants as described previously [22] . In the non-manifesting carrier group, the likelihood of prodromal disease being present was determined [23] . The study was approved by the University Health Network Research Ethics Board and informed consent was obtained from all participants.
Data acquisition
We obtained two audio recordings of sustained vocal phonation from each participant during a study visit at the Toronto Western Hospital using a USB powered microphone (Logitech, model 980186-0403) positioned on a stable surface ~2 inches from the participant's mouth. Recordings were collected using Audacity software (Version 2.0.3) in a quiet room. Participants with iPD were evaluated in the ON medication state. Each participant was instructed to "Take a deep breath and then let out a single "aaah" sound for as long as you can." Each recording was sampled at 44.1 kHz and stored as a de-identified digital audio file (.wav format).
Data processing
Identification of the longest usable segment of sustained phonation for each recording was performed manually. Recordings were discarded from the analysis if they were too noisy or if the phonation duration was shorter than two seconds. For each recording, we extracted 292 summary measures (also referred to as features or dysphonia measures) that have been used for analysing voice, including in PD [10, 14, 18, 24] . Details regarding these features are provided in the Supplementary section.
Statistical analysis
We identified 3 pairwise comparisons of interest: (1) LRRK2-PD versus iPD, (2) Nonmanifesting carriers versus related non-manifesting non-carriers, and, (3) Non-manifesting carriers versus healthy controls. For each pairwise comparison, salient features were identified using the following 5 feature selection algorithms that help enhance the explanatory power of the analysis by removing redundant and less informative features [25] [26] [27] [28] [29] . Each of the 5 feature selection algorithms provided a unique set of feature ranking. To obtain a single ranking of the most salient features to be used for group comparison, we used a majority voting scheme. Pairwise comparisons were performed using a highly nonlinear statistical machine learning algorithm (random forests), used to separate generic feature data into several different classes [30] . Discrimination accuracy was evaluated using a 10-fold cross-validation (CV) scheme (with 100 repetitions for statistical confidence). This scheme helps assess generalizability of the discrimination results to similar, but previously unseen data, and has been used in previous studies on voice analysis in PD [10, 14, 18] . Data was balanced in each cross-validation repetition to eliminate differences in group sample size. The statistical significance level was set to p=0.05. Statistical analysis of the voice recordings was performed using the Matlab® software (version 2016b). Details regarding statistical analysis focussing on feature extraction, feature selection, and validation are provided in the Supplementary section.
Results
LRRK2-PD vs idiopathic PD
On average, LRRK2-PD participants were older and had a longer disease duration compared to participants with iPD (Table 1) . However, UPDRSIII (motor UPDRS) between the two groups was similar. Two recordings were collected from each participant, however, 3 LRRK2-PD and 2 iPD voice recordings were discarded as they were too noisy for reliable computation of features. Accuracies to distinguish LRRK2 PD from iPD are reported in Table   1 and were computed using the 10 most salient features. Including more features in the classifier (random forest) improved the discrimination accuracy only marginally (Supplementary Figure 2) . In discriminating participants using 11 LRRK2-PD (n = 7 individuals) and 32 iPD voice recordings (n = 17 individuals), the mean sensitivity was 95.4% (Standard Deviation (SD) 17.8%) and mean specificity was 89.6% (SD 26.5%). Results were very similar for males and females (Table 1) ; in discriminating recordings from female participants, the mean sensitivity was 99.4% (SD 7.1%) and mean specificity was 85.7% (SD 34.1%), whereas for male participants, the mean sensitivity was 100% (SD 0%) and mean specificity was 88.9% (SD 31.6%). Stratification of data based on sex resulted in too few recordings to adequately fit the random forest classifier, which reduces the reliability of analysis and inference, particularly for LRRK2-PD (n = 7). Statistically significant differences were observed between LRRK2-PD and iPD voice features (see Figure 1 (showing clear separation plotting 2 salient features) and Supplementary Figure 1) . Details regarding the most salient features are provided (Supplementary Table 3 ).
Accuracies were also computed using leave-one-subject-out (LOSO) CV [31] . Using LOSO CV, the mean sensitivity was 83.7% and mean specificity was 88.5% in discriminating LRRK2-PD from iPD (see Supplementary Table 2 ).
We performed additional analysis whereby non-manifesting LRRK2 carriers and individuals with LRRK2-associated PD were treated as belonging to the same clinical group. This resulted in a larger sample of LRRK2 carriers (n=27) which helped improve statistical power. The rationale of this analysis was to investigate if vocal deficits in LRRK2 carriers (both manifesting and non-manifesting) were different from iPD (for details, see
Supplementary analysis).
Non-manifesting carriers (NMC) versus Related Non-carriers (RNC) and Controls
Participants from the three groups were of similar age (Table 1) . NMC had a higher UPDRSIII score compared to both healthy controls and RNC. Statistical analyses were performed using 39 NMC recordings (n = 20), 48 RNC recordings (n = 25), and 47 control recordings (n = 26).
In discriminating NMC from RNC, the mean sensitivity was 74.9% (SD 24.0%) and mean specificity was 78.0% (SD 23.3%). Moreover, in discriminating NMC from unrelated healthy controls, the mean sensitivity was 75.7% (SD 24.3%) and mean specificity was 81.8% (SD 20.4%). Scatterplots of the most salient features for these pairwise comparisons do not allow readily visible identification of this discrimination (Figure 1 ). Compared to LRRK2-PD and iPD features, therefore, the voice features for NMC, RNC, and healthy controls were much less discriminatory.
Discussion
Our preliminary analyses found statistically significant differences between LRRK2-PD and iPD (p<0.01) in features extracted from sustained phonations (Figure 1 and Supplementary   Figure 1 ). The differences in the features were less pronounced when non-manifesting carriers were compared with related non-carriers and healthy controls. Thus, voice could potentially be used as a non-invasive and inexpensive biomarker for identifying a LRRK2 mutation in PD participants, but seems to be less promising as a potential marker for the prodromal phase of LRRK2-PD.
A limitation of this study is the small sample size, particularly for participants with LRRK2-PD. We investigated and verified that unique participant identity was not a confounder (see Supplementary analysis) [32] . LRRK2-PD participants were older than iPD participants and we cannot rule out the effect of presbyphonia as a potential confound [33] . However, including age as a covariate in the classification model did not result in improved classification accuracy, indicating that if presbyphonia exists in this cohort its effects may be negligible. Moreover, the predictive accuracy obtained using machine learning algorithms and multiple features do not lead to ready etiologically-relevant explanations for why voice impairment might be discriminatory in this context [34] . This hinders our ability to make inferences regarding underlying pathophysiological changes associated with an impaired voice in PD.
We find that statistical analysis of sustained phonations help discriminate LRRK2-PD and iPD. The findings of this study add to the growing evidence supporting clinical and pathological differences between LRRK2-PD and iPD, whereby differences in both motor and nonmotor features (including heart rate variability, tremor, gait, olfactory identification) have been previously reported [35] [36] [37] [38] [39] [40] . To the best of our knowledge, this is the first proofof-concept study that investigates potential vocal deficits in manifesting and nonmanifesting LRRK2-carriers. These results warrant further investigation into the potential of using voice for the delineation of PD subtypes in larger cohorts. The table is presented in three different sections (A-C). Section A presents descriptive statistics for the five clinical groups (1. LRRK2-PD, 2. iPD, 3. NMC, 4. RNC, and, 5. Healthy controls). Section B compares the descriptive statistics. Age was analyzed using an unpaired t-test, whereas disease duration and UPDRSIII total were compared using Mann-Whitney U test. p values <0.05 are highlighted in the bold italic text. Section C presents the out-of-sample discrimination accuracy for the three priority pairwise comparisons (1. LRRK2-PD vs iPD, 2. NMC vs RNC, and, 3. NMC vs Healthy) using a 10-fold crossvalidation (CV) scheme (with 100 repetitions), employing only the 10 most salient voice features. The scheme involved repetitive splitting of the data into a training set (90% of the total observations) and a validation set (remaining 10% of the observations). The mean sensitivity and mean specificity across different CV repetitions are presented (along with standard deviation in brackets). The data was balanced to account for differences in group sample size. Accuracies were computed using all recordings, and separately for subgroup analysis using data stratified by sex. Panel A shows two highly discriminatory features that help differentiate LRRK2-PD from iPD. In Panel A, we plot Entropy (entropy computed after wavelet decomposition, quantifies extent of randomness in a signal) and Glottis to Noise Excitation (GNE, degree of signal strength versus noise resulting from incomplete vocal fold closure), both features were significantly different (p<0.001, denoted by ***) (Panel B). Panel C plots two salient features that help discriminate NMC from RNC. In Panel C, we plot Harmonic to Noise Ratio (HNR, signal to noise ratio) and median shimmer (roughness in voice). HNR between the two groups was significantly different (p<0.01, denoted by **), whereas shimmer between NMC and RNC was similar (p>0.05) (Panel D), which indicates that the two cohorts are less different (as reflected in the discrimination accuracies reported in Table 1 ). Panel E shows two salient features that discriminate NMC from healthy controls. In Panel E, we plot Mel Frequency Cepstral Coefficient (MFCC, quantifies vocal fold dynamics depending on properties of the articulators) and median shimmer. Panel F shows that MFCC and shimmer were significantly different between the two groups. Salient features were identified separately for each pairwise comparison, using five different feature selection algorithms. The above plots were generated using all usable voice recordings. p values reported above were computed using the nonparametric two-sided Kolmogorov-Smirnov (KS) test.
Supplementary material for 'Investigating Voice as a Biomarker for leucinerich repeat kinase 2-Associated Parkinson's Disease' Supplementary Analysis
Feature extraction
For each recording, we extracted 292 summary measures (also referred to as features).
These features can broadly be characterized as: (1) extended time-frequency domain properties. Details regarding these feature categories are provided in Supplementary Table 1 .
Feature selection
For each pairwise comparison, salient features were identified using the following 5 feature selection algorithms that help enhance the explanatory power of the analysis by removing redundant and less informative features: (1) Minimum redundancy maximum relevance (mRMR) [27] , (2) Gram-Schmidt orthogonalization (GSO) [25] , (3) RELIEF [26] , (4) Local learning-based feature selection (LLBFS) [28] , and (5) Least absolute shrinkage and selection operator (LASSO) [29] .
Validation
In this study, we used two model validation schemes: (1) 10-fold cross-validation: this scheme involves randomly splitting the data into two non-overlapping parts, the first part of the data (comprising 90% of the recordings) are used to train the model (i.e., learn the underlying differences in patterns of voice-based features for each pairwise comparison), while the remaining 10% of the recordings are used for validation (i.e., evaluate the accuracy of model predictions). This process of randomized selection of training and validation sets was repeated multiple times, and the discrimination accuracies (quantified using sensitivity and specificity) were calculated on each repetition. (2) Leave-one-subjectout: this scheme involves splitting the data such that all recordings from only one participant are used for model validation, while all remaining recordings are used for training. This process is repeated multiple times. Note that for both schemes, the accuracy of model predictions are computed using only the validation set. Basically, the model is blinded to the validation set during the training process, which helps gauge generalizability of the model to previously unseen similar datasets.
In this study, we analysed all available/suitable voice recordings leading to a mismatch in the five group sizes (Table 1) . Whilst there are fewer LRRK2-associated PD participants compared to iPD, it should be noted that we used a 'balanced cross-validation scheme' that results in an equal number of samples across different classes for each pairwise comparison.
This scheme helps mitigate the issues associated with imbalanced datasets/differences in group sizes.
LRRP2-PD vs idiopathic PD (excluding 1 LRRK2-PD participant)
LRRP2-PD participants had longer mean disease duration (n = 7, mean = 10.3 years, SD = 11.8 years) compared to participants with iPD (n = 17, mean = 5.4 years, SD = 5.8 years).
One LRRK2-PD participant had a disease duration of 36 years, and without this participant, the mean disease duration for the remaining 6 LRRK2-PD participants was 6 years (SD = 3.7 years), which is similar to the mean disease duration for iPD participants (5.4 years).
Statistical analyses were thus performed separately by excluding this LRRK2-PD participant (disease duration 36 years, female, age 85 years, one voice recording available). The rationale for this analysis was to investigate disease duration as a potential confounding factor in discriminating LRRK2-PD versus iPD. Using 10 voice recordings collected from the remaining 6 LRRK2-PD participants, we recomputed the accuracy in discriminating LRRK2-PD versus iPD.
Using only the 10 top-ranked features for this pairwise comparison, the mean sensitivity and mean specificity was 97.0% (SD 15.5%) and 87.2% (SD 31.1%) in discriminating LRRK2-PD from iPD using all recordings, 99.0% (SD 10.0%) and 82.4% (SD 38.1%) in discriminating LRRK2-PD from iPD using only female recordings, and 100% (SD 0%) and 88.9% (SD 31.6%) in discriminating LRRK2-PD from iPD using only male recordings. These accuracies were obtained using 10-fold cross-validation. Note that the excluded LRRK2-PD recording was collected from a female participant; hence the accuracy in discriminating LRRK2-PD versus iPD using only male recordings was the same as those reported in Table 1 . For leave-onesubject-out cross-validation, mean sensitivity and mean specificity were 88.5% (SD 7.8%) and 81.3% (SD 12.3%) respectively, in discriminating LRRK2-PD from iPD using all recordings.
The sample size was too small to draw any reliable inference based on discrimination accuracies for subgroup analysis stratified by sex. These sensitivity and specificity values (obtained using recordings from n = 6 LRRK2-PD participants) are in close agreement with the discrimination accuracies obtained using all available recordings for LRRK2-PD (n = 7), as reported in Table 1 and Supplementary Table 2 . Encouragingly, for all pairwise comparisons reported above, the sensitivity and specificity results differed statistically significantly from comparable results obtained from completely randomized predictions about which participants had a LRRK2 mutation or were iPD (these predictions are akin to outcomes of an unbiased coin flip and are based on chance alone). Moreover, the differences in LRRK2-PD and iPD voice recordings is also evident from the scatterplot of salient features that shows two distinct clusters, as presented in Supplementary Figure 4 .
Detecting and characterising identity confounding
Digital recordings of voice and other sensor data from individuals can capture properties of these data which are unique to particular individuals, in the following way. indicating that this form of identity confounding is unlikely to be a significant factor in the results presented in this study.
Prodromal versus Nonprodromal
We investigated if two non-manifesting carriers classified as being in the prodromal state were more similar to their non-prodromal counterparts compared to participants with LRRK2-PD. One of the two participants meeting prodromal criteria was more similar to the manifesting LRRK2 carriers on the basis of the two most salient voice features, (Supplementary Figure 3) . However, the sample size was too small to draw any reliable inferences. 
LRRK2 carriers vs idiopathic PD
Wavelet related measures
Variants of above-discussed summary measures applied to wavelet coefficients of the speech signal SUPPLEMENTARY TABLE 2. Discrimination accuracy for the leave-one-subject-out (LOSO) crossvalidation (CV) scheme for the three pairwise comparisons: LRRK2-associated Parkinson's disease (LRRK2-PD) versus idiopathic PD (iPD), non-manifesting LRRK2 mutation carriers (NMC) versus related non-carriers (RNC), and NMC versus healthy controls, computed using a machine learning algorithm (random forest) and a naïve benchmark (randomized predictions). The above sensitivity and specificity values were computed separately for each of the three priority pairwise comparisons (1. LRRK2-PD vs iPD, 2. NMC vs RNC, and, 3. NMC vs Healthy) using a leave-one-subject-out (LOSO) cross-validation (CV) scheme, employing 10 most salient voice features. Validation scheme involved repetitive splitting of the data such that at a given CV iteration, all voice tests from only one randomly selected participant were employed for model validation, while voice tests from all remaining participants were used for training. We used LOSO CV scheme with 100 repetitions. The data was balanced to account for differences in number of participants in each clinical group. Accuracies are reported for a machine learning classifier (random forest) and a naïve benchmark based on randomized predictions (expected accuracy around 50%), using all available voice tests from the five clinical groups (1. LRRK2-PD, 2. iPD, 3. NMC, 4. RNC, and, 5. Healthy controls). The sensitivity and specificity values were presented in percentage (%) as mean (and standard deviation, in brackets), whereby the standard deviation denotes the variability in the accuracy across multiple CV repetitions. The rankings of the most salient features were obtained separately for each of the three pairwise comparisons, using a majority voting scheme (using 5 feature selection algorithms). Quantifies mostly higher harmonic components in the signal Wavelet energy of the 7 th wavelet coefficient Wavelet log energy the 6 th detail wavelet decomposition coefficient, quantifies changes in F0 P0
Discrimination accuracy
Perturbation quotient (zeroth order) HNR (1) Harmonics to Noise Ratio, quantifies signal to noise, i.e. the extent of vocal noise using standard autocorrelation SUPPLEMENTARY FIGURE 1. Scatterplots and boxplots of salient features for the pairwise comparison:
LRRK2-associated Parkinson's disease (LRRK2-PD) versus idiopathic PD (iPD).
Panel A plots two salient features, Skewness (amplitude) and Vocal Fold Excitation Ratio (VFER, the degree of signal strength over noise resulting from incomplete vocal fold closure), both skewness and VFER were significantly different between the two groups, (p<0.001, denoted by ***) (Panel B). Panel C plots mean Teager Kaiser Energy Operator (TKEO, quantifies instantaneous changes in voice energy) and a Wavelet coefficient (based on TKEO), while Panel D shows that these features were significantly different between LRRK2-PD and iPD. Panel E plots the Mel Frequency Cepstral Coefficients (MFCC, quantifies vocal fold dynamics taking into account the properties of the articulators) and Entropy (entropy computed after wavelet decomposition, computes the extent of randomness in a signal), while Panel F shows that these features were statistically significantly different (p<0.01). Features with high discriminatory power were identified using five different feature selection algorithms. The above plots were generated using all voice recordings collected from participants with LRRK2-PD and iPD. p values reported above were computed using the nonparametric two-sided Kolmogorov-Smirnov (KS) test. 
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SUPPLEMENTARY FIGURE 2. Discrimination accuracies as a function of the number of salient features used in the machine learning discrimination analysis, for the three pairwise comparisons: LRRK2-associated Parkinson's disease (LRRK2-PD) versus idiopathic PD (iPD) (Panels A and B), nonmanifesting LRRK2 mutation carriers (NMC) versus related non-carriers (RNC) (Panels C and D), and NMC versus healthy controls (Panels E and F).
The above accuracies were computed using all available voice recordings from the five clinical groups (1. LRRK2-PD, 2. iPD, 3. NMC, 4. RNC, and, 5. Healthy controls), using 10-fold cross-validation (100 repetitions). The rankings of the most salient features were obtained using a majority voting scheme (using 5 feature selection algorithms). The feature rankings were obtained separately for each of the above 3 pairwise comparisons (1. LRRK2-PD vs iPD, 2. NMC vs RNC, and, 3. NMC vs Healthy). Features were added into the machine learning classifier (random forest) in increments of 2 (starting from 2, and going up to 30), whereby higher ranked features were added first. The whole process of training and validation was repeated each time two new features were included. Mean sensitivity and specificity values are denoted as grey circles and reported in percentage (%). The feature rankings were obtained separately for the above pairwise comparison: LRRK2-PD versus NMC. We analysed three voice recordings from two prodromal participants (denoted as a grey square). We analysed 10 voice recordings collected from six LRRK2-PD participants (denoted as grey crosses) and 32 voice recordings obtained from seventeen iPD participants (denoted as light grey circles). Analysis excluded one LRRK2-PD participant who had disease duration of 36 years, note that we only had one decent quality voice recording for this participant (denoted as a dark grey circle). 
